Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esmolol cardioplegia in CABG myocardial protection study
IRCT20180428039456N1Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Aug 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of esmolol in coronary arteriosclerosis (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Faster healing in patients undergoing cardiac surgery and Biochemical markers of myocardial injury. Started Aug 2019; status: completed.
02
Drugs
esmolol
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on IRCT20180428039456N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180428039456N1.